Home / Health / Semaglutide Cuts Heart Risk in Non-Diabetics
Semaglutide Cuts Heart Risk in Non-Diabetics
8 Apr
Summary
- Once-weekly semaglutide reduced cardiovascular events by 20%.
- Trial included adults with BMI 27+ and existing heart disease.
- Trial excluded participants with diabetes.
The SELECT trial, a significant study published in The New England Journal of Medicine, revealed that once-weekly semaglutide administration led to a 20% reduction in major cardiovascular events. This benefit was observed in adults who had a body mass index (BMI) of 27 or higher and suffered from pre-existing cardiovascular disease, specifically excluding individuals with diabetes.
The trial, spearheaded by A. Michael Lincoff, enrolled 17,604 participants and monitored their health outcomes over a period of approximately 40 months. The findings suggest semaglutide's potential in cardiovascular risk reduction for a specific patient group.
However, experts like Aditi Kantipuly of McGill University noted that the BMI threshold used in the trial might not be suitable for application in countries like India. This could potentially lead to the exclusion of at-risk patients who do not meet the 27 BMI criteria.
